22q11.2 Deletion Syndrome Market Trends Point to Steady Growth Ahead by 2036, DelveInsight Analysis Reveals | Nobias Therapeutics, Zynerba Pharma, Bausch Health Americas, Inc

Posted on
by

22q11.2 Deletion Syndrome Market Trends Point to Steady Growth Ahead by 2036, DelveInsight Analysis Reveals | Nobias Therapeutics, Zynerba Pharma, Bausch Health Americas, Inc
The Key 22q11.2 Deletion Syndrome Companies in the market include – Zynerba Pharmaceuticals, Inc., Nobias Therapeutics, Inc., Bausch Health Americas, Inc., and others.

 

DelveInsight’s “22q11.2 Deletion Syndrome Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the 22q11.2 Deletion Syndrome, historical and forecasted epidemiology as well as the 22q11.2 Deletion Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

Get a Free sample for the 22q11.2 Deletion Syndrome Market Report:

https://www.delveinsight.com/report-store/22q112-deletion-syndrome-market

 

Some of the key facts of the 22q11.2 Deletion Syndrome Market Report:

  • The 22q11.2 Deletion Syndrome market size was valued at nearly USD 14 million in 2025 and is anticipated to register a CAGR of 32% during the forecast period from 2026 to 2036.

  • In April 2025, ZYN002 is the first pharmaceutically produced synthetic cannabidiol formulated as a patented permeation-enhanced gel for transdermal absorption directly through the skin into the bloodstream—completely free of THC. Unlike cannabis-derived products, ZYN002 is synthetically manufactured in a cGMP-certified facility and does not cause the psychoactive effects associated with THC. If approved, it may qualify as a nonscheduled medication. The active compound, cannabidiol, has been granted Orphan Drug Designation by both the U.S. FDA and the European Medicines Agency (EMA) for Fragile X Syndrome (FXS) and 22q11.2 deletion syndrome (22q). Moreover, ZYN002 has also received FDA Fast Track designation for addressing behavioral symptoms in FXS.

  • Among the 7MM, the US accounted for the largest market size of 22q11.2 Deletion Syndrome. i.e., ~USD 8 million in 2025.

  • In EU4 and the UK, Germany and the UK captured the largest share of 22q11.2 deletion syndrome market, while Spain accounted for the least share.

  • The entry of NB-001 is expected capture a significant share in the 22q11.2 Deletion Syndrome landscape.

  • It is a lifelong condition and the most common chromosomal microdeletion syndrome, significantly impacting development, cognition, and behavioral health, with an estimated prevalence of ~1 in 4,000 live births.

  • A substantial proportion of patients experience neurocognitive impairment and psychiatric disorders, including a markedly elevated risk of schizophrenia (~25% in adults), making 22q11.2DS one of the strongest known genetic risk factors for severe mental illness.

  • According to DelveInsight’s estimates, in 2025, the total number of diagnosed prevalent cases of 22q11.2 deletion syndrome in the 7MM was ~ 101,500.

  • In the United States, among age-specific diagnosed prevalent cases of 22q11.2 deletion syndrome, infant accounted for the majority of cases (~12,550), followed by 1 ̶ 5 years (~10,300), 6 ̶ 12 years (~19,550), 18+ years (~7,000), and 13 ̶ 17 years (~4,800) in 2025.

  • Among EU4 and the UK Germany accounted for the highest number of diagnosed prevalent cases of 22q11.2 Deletion Syndrome (~9,300 cases), while Spain reported the lowest burden (~6,100 cases) in 2025, highlighting regional variability in diagnosis and disease recognition.

  • In Japan, the diagnosed prevalent cases of 22q11.2 deletion syndrome with behavioral and psychiatric phenotypes were approximately 7,650 in 2025.

  • Key 22q11.2 Deletion Syndrome Companies: Zynerba Pharmaceuticals, Inc., Nobias Therapeutics, Inc., Bausch Health Americas, Inc., and others

  • Key 22q11.2 Deletion Syndrome Therapies: ZYN002, NB-001, Metyrosine, and others

  • The 22q11.2 Deletion Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage 22q11.2 Deletion Syndrome pipeline products will significantly revolutionize the 22q11.2 Deletion Syndrome market dynamics.

 

22q11.2 Deletion Syndrome Overview

22q11.2 Deletion Syndrome, also known as DiGeorge Syndrome or Velocardiofacial Syndrome, is a genetic disorder caused by the deletion of a small segment of chromosome 22. It can lead to a wide range of symptoms, including heart defects, immune system problems, developmental delays, speech and language difficulties, and learning challenges. Individuals with this syndrome may also have distinct facial features and may be at a higher risk for psychiatric conditions. The severity and range of symptoms can vary greatly, and treatment focuses on addressing specific health concerns and providing supportive care.

 

To Know in detail about the 22q11.2 Deletion Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; 22q11.2 Deletion Syndrome Market Forecast

 

22q11.2 Deletion Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

22q11.2 Deletion Syndrome Epidemiology Segmentation:

The 22q11.2 Deletion Syndrome market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

  • Total Prevalence of 22q11.2 Deletion Syndrome

  • Prevalent Cases of 22q11.2 Deletion Syndrome by severity

  • Gender-specific Prevalence of 22q11.2 Deletion Syndrome

  • Diagnosed Cases of Episodic and Chronic 22q11.2 Deletion Syndrome

 

Download the report to understand which factors are driving 22q11.2 Deletion Syndrome epidemiology trends @ 22q11.2 Deletion Syndrome Epidemiology Forecast

 

22q11.2 Deletion Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the 22q11.2 Deletion Syndrome market or expected to get launched during the study period. The analysis covers 22q11.2 Deletion Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the 22q11.2 Deletion Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

22q11.2 Deletion Syndrome Therapies and Key Companies

  • RETHYMIC (formerly RVT-802): Sumitomo Pharma/Enzyvant/Roivant Sciences

  • NB-001: Nobias Therapeutics

  • ZYN002: Zynerba Pharmaceuticals, Inc.

  • NB-001: Nobias Therapeutics, Inc.

  • Metyrosine: Bausch Health Americas, Inc.

 

Discover more about therapies set to grab major 22q11.2 Deletion Syndrome market share @ 22q11.2 Deletion Syndrome Treatment Market

 

22q11.2 Deletion Syndrome Market Drivers

  • 22q11.2 deletion syndrome is a rare genetic condition; thus, companies developing treatment options for the same can possess several advantages like 7-year market exclusivity, orphan drug designation, and others.

 

22q11.2 Deletion Syndrome Market Barriers

  • There exists no approved treatment for the syndrome, as a result, there are several chances for the companies to investigate unmet requirements and develop therapeutic choices that will benefit the patient population and leverage this prevalent orphan indication.

 

Scope of the 22q11.2 Deletion Syndrome Market Report

  • Study Period: 2022–2036

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key 22q11.2 Deletion Syndrome Companies: Zynerba Pharmaceuticals, Inc., Nobias Therapeutics, Inc., Bausch Health Americas, Inc., and others

  • Key 22q11.2 Deletion Syndrome Therapies: ZYN002, NB-001, Metyrosine, and others

  • 22q11.2 Deletion Syndrome Therapeutic Assessment: 22q11.2 Deletion Syndrome current marketed and 22q11.2 Deletion Syndrome emerging therapies

  • 22q11.2 Deletion Syndrome Market Dynamics: 22q11.2 Deletion Syndrome market drivers and 22q11.2 Deletion Syndrome market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • 22q11.2 Deletion Syndrome Unmet Needs, KOL’s views, Analyst’s views, 22q11.2 Deletion Syndrome Market Access and Reimbursement

 

To know more about 22q11.2 Deletion Syndrome companies working in the treatment market, visit @ 22q11.2 Deletion Syndrome Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. 22q11.2 Deletion Syndrome Market Report Introduction

2. Executive Summary for 22q11.2 Deletion Syndrome

3. SWOT analysis of 22q11.2 Deletion Syndrome

4. 22q11.2 Deletion Syndrome Patient Share (%) Overview at a Glance

5. 22q11.2 Deletion Syndrome Market Overview at a Glance

6. 22q11.2 Deletion Syndrome Disease Background and Overview

7. 22q11.2 Deletion Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of 22q11.2 Deletion Syndrome

9. 22q11.2 Deletion Syndrome Current Treatment and Medical Practices

10. 22q11.2 Deletion Syndrome Unmet Needs

11. 22q11.2 Deletion Syndrome Emerging Therapies

12. 22q11.2 Deletion Syndrome Market Outlook

13. Country-Wise 22q11.2 Deletion Syndrome Market Analysis (2022–2036)

14. 22q11.2 Deletion Syndrome Market Access and Reimbursement of Therapies

15. 22q11.2 Deletion Syndrome Market Drivers

16. 22q11.2 Deletion Syndrome Market Barriers

17. 22q11.2 Deletion Syndrome Appendix

18. 22q11.2 Deletion Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

 

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/